sq-11725 has been researched along with carvedilol in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Amend, A; Candelore, MR; Cascieri, MA; Deng, L; Guan, XM; Liu, Y; Newbold, R; Tota, L; Weber, AE | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Baker, JG | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, WC; Lo, GH; Wang, HM; Yu, HC | 1 |
| Bond, RA; Bouvier, M; Forkuo, GS; Joshi, R; Knoll, BJ; Leff, P; Parra, S; Thanawala, VJ; Valdez, DJ | 1 |
| Bond, RA; Eikenburg, DC; Joshi, R; Kim, H; Knoll, BJ; Valdez, D | 1 |
| Hayes, P; Robertson, M | 1 |
| Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP | 1 |
| Driessen, RJB; Logger, JGM; Olydam, JI | 1 |
| Jacobsen, SJ; Kalantar-Zadeh, K; Kovesdy, CP; Lee, MS; Neyer, JR; Shaw, SF; Shi, J; Sim, JJ; Zhou, H | 1 |
2 review(s) available for sq-11725 and carvedilol
| Article | Year |
|---|---|
Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Nadolol; Primary Prevention; Propranolol; Randomized Controlled Trials as Topic; Secondary Prevention | 2018 |
Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Bradycardia; Carvedilol; Dermatologic Agents; Drug Evaluation; Erythema; Facial Dermatoses; Flushing; Humans; Hypotension; Nadolol; Propranolol; Retrospective Studies; Rosacea; Treatment Outcome | 2020 |
1 trial(s) available for sq-11725 and carvedilol
| Article | Year |
|---|---|
Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Chi-Square Distribution; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hemostasis, Endoscopic; Humans; Hypertension, Portal; Isosorbide Dinitrate; Kaplan-Meier Estimate; Ligation; Male; Middle Aged; Nadolol; Propanolamines; Proportional Hazards Models; Secondary Prevention; Vasodilator Agents | 2012 |
14 other study(ies) available for sq-11725 and carvedilol
| Article | Year |
|---|---|
Potent and selective human beta(3)-adrenergic receptor antagonists.
Topics: Adipocytes; Adrenergic beta-Antagonists; Aminophenols; Animals; Binding, Competitive; CHO Cells; Cloning, Molecular; Cricetinae; Cyclic AMP; Humans; Ligands; Lipolysis; Macaca mulatta; Receptors, Adrenergic, beta; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3; Structure-Activity Relationship; Sulfonamides | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
β-Blockers have differential effects on the murine asthma phenotype.
Topics: Adrenergic beta-Antagonists; Allergens; Alprenolol; Animals; Asthma; Bronchoalveolar Lavage Fluid; Carbazoles; Carvedilol; Cell Count; Epinephrine; Female; Male; Mice, Knockout; Models, Biological; Mucins; Nadolol; Ovalbumin; Phenotype; Propanolamines; Propranolol | 2015 |
Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype.
Topics: Adrenergic beta-Antagonists; Animals; Asthma; Carbazoles; Carvedilol; Disease Models, Animal; Inflammation; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nadolol; Ovalbumin; Phenotype; Phosphorylation; Propanolamines; Pyroglyphidae; Respiratory Hypersensitivity | 2017 |
Primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Nadolol; Propanolamines; Propranolol | 2018 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Death; Cohort Studies; Female; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Labetalol; Logistic Models; Male; Metoprolol; Middle Aged; Mortality; Nadolol; Proportional Hazards Models; Propranolol; Protective Factors; Renal Dialysis; Retrospective Studies; Risk; Risk Factors | 2021 |